# Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans

> **NCT04649515** · PHASE3 · TERMINATED · sponsor: **Tychan Pte Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Coronavirus Disease-2019 (COVID-19)

## Interventions

- **BIOLOGICAL:** TY027
- **BIOLOGICAL:** TY027
- **OTHER:** 0.9% saline

## Key facts

- **NCT ID:** NCT04649515
- **Lead sponsor:** Tychan Pte Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-04
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Low recruitment rate
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649515, "Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04649515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*